Ardent Health faces securities class action lead plaintiff deadline March 9, 2026

Reuters
Feb 26
Ardent Health faces securities class action lead plaintiff deadline March 9, 2026

Ardent Health Inc. is facing a securities class action lawsuit in the U.S. District Court for the Middle District of Tennessee. The suit alleges the company and certain executives failed to disclose material information during a class period from July 18, 2024 to Nov. 12, 2025. The claims follow Ardent’s disclosure of a $43 million third-quarter 2025 revenue decrease tied to accounts receivable collectability after a new revenue accounting system transition, a reduction in 2025 EBITDA guidance, and a $54 million increase in professional liability reserves; shares fell nearly 34% the next day. Lead plaintiff applications are due March 9, 2026, in Postiwala v. Ardent Health, Inc., et al., No. 26-cv-00022.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ardent Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602252154PRIMZONEFULLFEED9661817) on February 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10